Nifty Corporate Earnings Analysis –
Q4 | 2016
by Rajat Sharma | May 12, 2016
Yesterday we analyzed earnings trend for constituent companies of the S&P CNX Nifty. On year-on-year basis (Q4 2015 to Q4 2016) corporate earnings showed a growth of 14.7%. In comparison, average stock prices went down by 1.9% during the same period*.
* Based on stock prices as on 31st March for each year.
** Based on 26 of the 50 companies comprising the S&P CNX Nifty that have declared results as of the date of this article.
Current PE Valuation of the Nifty = 21.30
Excel Calculation – 26 Nifty Company Result
Key Points about Corporate Earnings for Q4:
- The analysis is based on the results of 26 out of 50 Nifty companies which have declared earnings so far.
- Note – from April 1, 2016, Nifty has excluded Cairn, Vedanta, and PNB and included Aurobindo Pharma, Bharti Infratel, and Eicher Motors
- Earnings are improving while stock prices are showing a declining trend.
- On year-on-year basis there is an average growth of 14.7% in profitability. The benchmark Nifty went down 9 % in the same period.
- On a trailing basis markets remain expensive and are trading at valuations of 21.30 (PE).
- Most sectors have shown considerable improvement in profitability.
- Fundamentally (besides valuations) things are looking good at macro level.
- Pharma, Metals, Construction, Oil and Gas , Power companies are yet to announce their earnings for Q4 of FY 2016.
WE WILL BE UPDATING THIS ARTICLE ONCE REST OF THE COMPANIES DECLARE THEIR RESULTS OVER THE NEXT 1 MONTH.
BOOKMARK THIS SPACE.
Share this post
Don’t forget to leave a comment
Don’t forget to leave a comment
Other Posts
Other Posts
The Next Big Thing for Indian Pharma Stocks – Fat Loss Pills
Until about a decade back, FMCG and pharma stocks were considered the most lucrative investment options. Over the past 10 years however, pharma stocks have underperformed the broader markets. The sector as a whole has genereated a lot of interest in recent times. This...
Why is Unitech Stock Rising?
Unitech got into financial constraints and mismanagement as has been alleged sometime from 2013-2014 onwards, which resulted in non-delivery of sold units to the Homebuyers. This followed litigation at various fora and the promoters were lodged in jail in 2017....
Mold-Tek Packaging- Proxy play for FMCG and Pharma
VALUATIONS We maintain a positive view on Mold-Tek Packaging. Our Call - Buy We expect a 36% upside due to the company's earnings being at an inflection point. Mold-Tek Packaging is expected to show superior volume growth and margin improvement, supported by capacity...
Free Investment Newsletter
Join us and connect with over 65,000 subscribers who benefit from our insights on the latest
in the world of stocks and personal finance.
Free Investment Newsletter
Join us and connect with over 65,000 subscribers who benefit from our insights on the latest
in the world of stocks and personal finance.
0 Comments